SIRT2 and Parkinson disease: Based on prior studies demonstrating the benefits of Sirt2 inhibition in neurodegenerative diseases with inhibitors targeting the Sirt2 NAD+ binding site [129,130,151,152,153], two nicotinamide analogs with predicted brain permeability were tested in an α-synuclein toxicity model of Parkinson’s disease in SH-SY5Y neuroblastoma cells [128].